Table 4.
Outcomes in subgroups
|
A Subgroup analysis in patients treated with PCI ad hoc | |||
|---|---|---|---|
| Clopidogrel | Ticagrelor | P value | |
| (n = 244) | (n = 200) | ||
| Any Bleeding | 62 (25.4) | 54 (27.0) | 0.70 |
| TIMI minimal | 32 (13.1) | 28 (14.0) | 0.93 |
| TIMI minor | 30 (12.3) | 26 (13.0) | |
| TIMI major | 0 (0.0) | 0 (0.0) | |
| BARC type 1 | 32 (13.1) | 28 (14.0) | 0.79 |
| BARC type 2 | 29 (11.9) | 26 (13.0) | |
| BARC type 3a+3b | 1 (0.4) | 0 (0.0) | |
| BARC type 4+5 | 0 (0.0) | 0 (0.0) | |
| MACE 30d | 7 (2.9) | 9 (4.5) | 0.36 |
| MI | 6 (2.5) | 9 (4.5) | 0.24 |
| Periprocedural MI | 6 (2.5) | 8 (4.0) | 0.36 |
| ST | 0 (0.0) | 1 (0.5) | 0.45 |
| Stroke | 1 (0.4) | 0 (0.0) | 1.0 |
| Death | 0 (0.0) | 0 (0.0) | − |
|
| |||
|
B Subgroup analysis in patients undergoing CA only or CA with diagnostic procedure | |||
| Clopidogrel | Ticagrelor | p value | |
| (n = 333) | (n = 226) | ||
|
| |||
| Any Bleeding | 70 (21.0) | 39 (17.3) | 0.27 |
| TIMI minimal | 47 (14.1) | 24 (10.6) | 0.46* |
| TIMI minor | 23 (6.9) | 15 (6.6) | |
| TIMI major | 0 (0.0) | 0 (0.0) | |
| BARC type 1 | 47 (14.1) | 24 (10.6) | 0.38** |
| BARC type 2 | 23 (6.9) | 14 (6.2) | |
| BARC type 3a+3b | 0 (0.0) | 1 (0.4) | |
| BARC type 4+5 | 0 (0.0) | 0 (0.0) | |
| MACE 30d | 0 (0.0) | 1 (0.4) | 0.40 |
| MI | 0 (0.0) | 1 (0.4) | |
| Periprocedural MI | 0 (0.0) | 0 (0.0) | |
| ST | 0 (0.0) | 0 (0.0) | |
| Stroke | 0 (0.0) | 0 (0.0) | |
| Death | 0 (0.0) | 0 (0.0) | |
Results are presented as numbers and (percentages). PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; BARC, Bleeding Academic Research Consortium; MACE, major adverse cardiovascular events (includes death, ST, MI, and stroke within 30 days); MI, myocardial infarction.
*
Statistical test for all TIMI bleedings.
**
Statistical test for all BARC bleedings.